Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors.

MDM2 and MDMX are oncoproteins that negatively regulate the activity and stability of the tumor suppressor protein p53. The inhibitors of protein-protein interactions (PPIs) of MDM2-p53 and MDMX-p53 represent potential anticancer agents. In this study, a novel approach for identifying MDM2-p53 and MDMX-p53 PPI inhibitor candidates by affinity-based screening using a chemical array has been established. A number of compounds from an in-house compound library, which were immobilized onto a chemical array, were screened for interaction with fluorescence-labeled MDM2 and MDMX proteins. The subsequent fluorescent polarization assay identified several compounds that inhibited MDM2-p53 and MDMX-p53 interactions.

[1]  U. Francke,et al.  Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line , 1987, Somatic cell and molecular genetics.

[2]  D. George,et al.  Stabilization of the MDM2 Oncoprotein by Interaction with the Structurally Related MDMX Protein* , 1999, The Journal of Biological Chemistry.

[3]  M. Oren,et al.  Mdm2 promotes the rapid degradation of p53 , 1997, Nature.

[4]  Hiroyuki Osada,et al.  A small-molecule inhibitor shows that pirin regulates migration of melanoma cells. , 2010, Nature chemical biology.

[5]  Xinjiang Wang.  p53 regulation: Teamwork between RING domains of Mdm2 and MdmX , 2011, Cell cycle.

[6]  G. Wahl,et al.  A New Twist in the Feedback Loop: Stress-Activated MDM2 Destabilization is Required for p53 Activation , 2005, Cell cycle.

[7]  M. Oren,et al.  The p53-Mdm2 module and the ubiquitin system. , 2003, Seminars in cancer biology.

[8]  T. Kigawa,et al.  A Fluorescent-Based High-Throughput Screening Assay for Small Molecules That Inhibit the Interaction of MdmX with p53 , 2013, Journal of biomolecular screening.

[9]  M. Matsuoka,et al.  Affinity selection and sequence-activity relationships of HIV-1 membrane fusion inhibitors directed at the drug-resistant variants , 2010 .

[10]  Kristian Helin,et al.  Amplification of Mdmx (or Mdm4) Directly Contributes to Tumor Formation by Inhibiting p53 Tumor Suppressor Activity , 2004, Molecular and Cellular Biology.

[11]  M. Uttamchandani,et al.  Current advances in peptide and small molecule microarray technologies. , 2012, Current opinion in chemical biology.

[12]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[13]  A. Levine,et al.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.

[14]  D. Bashford,et al.  Identification and Characterization of the First Small Molecule Inhibitor of MDMX* , 2010, The Journal of Biological Chemistry.

[15]  G. Wahl,et al.  MDM2, MDMX and p53 in oncogenesis and cancer therapy , 2013, Nature Reviews Cancer.

[16]  Xuejun Jiang,et al.  MdmX Protein Is Essential for Mdm2 Protein-mediated p53 Polyubiquitination , 2011, The Journal of Biological Chemistry.

[17]  A. Jochemsen,et al.  MDMX: a novel p53‐binding protein with some functional properties of MDM2. , 1996, The EMBO journal.

[18]  Chong Li,et al.  Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX , 2009, Proceedings of the National Academy of Sciences.

[19]  Chong Li,et al.  A left-handed solution to peptide inhibition of the p53-MDM2 interaction. , 2010, Angewandte Chemie.

[20]  H. Osada,et al.  Robust and Systematic Drug Screening Method Using Chemical Arrays and the Protein Library: Identification of Novel Inhibitors of Carbonic Anhydrase II , 2008, Bioscience, biotechnology, and biochemistry.

[21]  Michael A. Dyer,et al.  MDMX: from bench to bedside , 2007, Journal of Cell Science.

[22]  Hirofumi Tanaka,et al.  Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53 , 1997, FEBS letters.

[23]  G. Wahl,et al.  MDM2 and MDM4: p53 regulators as targets in anticancer therapy. , 2007, The international journal of biochemistry & cell biology.

[24]  G. Dubin,et al.  High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx , 2009, Cell cycle.

[25]  G. Wahl,et al.  Regulating the p53 pathway: in vitro hypotheses, in vivo veritas , 2006, Nature Reviews Cancer.

[26]  Chandra S Verma,et al.  Differential binding of p53 and nutlin to MDM2 and MDMX: Computational studies , 2010, Cell cycle.

[27]  Weirong Yuan,et al.  Interrogation of MDM2 phosphorylation in p53 activation using native chemical ligation: the functional role of Ser17 phosphorylation in MDM2 reexamined. , 2012, Journal of the American Chemical Society.

[28]  H. Osada,et al.  Immobilization of natural products on glass slides by using a photoaffinity reaction and the detection of protein-small-molecule interactions. , 2003, Angewandte Chemie.

[29]  Bert Vogelstein,et al.  Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53 , 1993, Nature.